Kornimate/medical-research-clean huggingface dataset:
clinical predictors for venous thromboembolism in patients with a history of thrombosis (predictors)

Conditions: Thromboembolic Disease Recurrent; Deep Vein Thrombosis; Pulmonary Embolism; Venous Thromboembolism; Recurrent Thromboembolic Disease

Summary: patients with a history of blood clots are at risk of developing additional clots in the future. doctors use a tool called a clinical decision rule to tell them how likely it is that a patient has a blood clot and if they should have further testing to look for the clot. this tool may cause doctors to over-diagnosis a recurrent clot because the symptoms may be left over from the previous clot. correctly diagnosing a recurrent blood clot is very important since there are risks associated with both over-diagnosis and under-diagnosis. if a recurrent blood clot is missed (under-diagnosis) the patient is at risk of death from a clot in the lungs. if blood thinners are prescribed when they are not needed (over-diagnosis), the patient may have to take blood thinners for their lifetime and risk having serious bleeding.

several tools have been developed to standardize the diagnostic management of a suspected first blood clot. one of these tools is the use of a clinical decision rule. clinical decision rules have been designed to help clinicians make diagnostic and therapeutic decisions at the bedside. a score is computed on the presence of some criteria from the patient's medical history, clinical signs and symptoms. the score provides the probability of a blood clot. the rules can be used in combinations with a simple blood test - called d-dimer - to identify patients at low risk who don't require diagnostic imaging testing. benefits include reduced costs, length in hospital and radiation exposure. patients with prior blood clots have been shown to be less likely to benefit from the non-invasive testing. therefore, they often need to undergo imaging tests, which are frequently difficult to interpret in patients with prior blood clots since residual clots are often present and are difficult to distinguish from a recurrent clot. the objective of this study is to try to prospectively assess the role of existing clinical decision rules in patients with prior blood clots, and to attempt to improve them in order to increase the yield of non-invasive testing and to reduce the risk of over-diagnosis with imaging tests. with respect to this study, clots within the deep veins of the legs are called deep vein thrombosis (dvt), while clots in the lungs are called pulmonary embolism (pe).

Eligibility criteria:
inclusion criteria: * outpatients with clinically suspected acute recurrent dvt or pe regardless of whether the previous event was a dvt or pe * age ≥18 years old * willing and able to give informed consent exclusion criteria: * life expectancy less than 3 months * suspicion of upper extremity thrombosis or thrombosis at an unusual site (e.g. cerebral or abdominal venous thrombosis) * previous vte was distal dvt or subsegmental pe * suspected recurrent vte is asymptomatic * previously enrolled in this study
ambulatory polysomnography in neurodiverse children: feasibility, quality, and satisfaction

Conditions: Neurodevelopmental Disorders; Pediatric Sleep Apnea; Periodic Leg Movements, Excessive, Sleep-Related; Polysomnography

Summary: laboratory polysomnography is the gold standard for objective sleep measurement. with hospital waiting times becoming increasingly long, outpatient polysomnography seems a good solution. children are at greater risk of developing sleep disorders and polysomnography in the hospital laboratory can be a stressful examination for these children and their parents. this can be even more the case in populations of children with neurodevelopmental disorders, such as attention deficit disorder with or without hyperactivity (adhd), or dys- learning disorders. several studies have already demonstrated the feasibility of ambulatory, in a home setting, polysomnography in children. the objective of this study is to demonstrate the acceptability and satisfaction of performing polysomnography at home on a large cohort of children, including children with neurodevelopmental disorders.


Eligibility criteria:
inclusion criteria: * all consecutive children who underwent a h-psh * age beetween 2 and 17 years old exclusion criteria: * no signed informed consent form for study participation

Keywords: home unattended polysomnography attention deficit disorder attention deficit hyperactivity disorder learning disorders
influence of radial extracorpeal shock wave in hemiplegic shoulder patients

Conditions: Hemiplegia; Spastic

Summary: the purposes of this study are to examine sonographic structural changes pre and post the radial extracorporeal shock wave intervention in hemiplegic shoulder pain, and to assess the relationships between sonographic structural changes and hemiplegic shoulder pain.

painful shoulder is a common complication following hemiplegic stroke. this pain may interfere with functional improvement, the patient's quality of life, and it may impede the process of rehabilitation. further understanding of rotator cuff tendon impairment and other shoulder soft tissue structural abnormalities in stroke patients may help clinicians in assigning more complete therapeutic plans to hemiplegic patients. the radial extracorporeal shock wave therapy has promising results in patients with musculoskeletal problems and in those with various causes of hsp, including spasticity, rotator cuff problems, adhesive capsulitis, and complex regional pain syndrome .the purposes of this study are to examine sonographic structural changes pre and post the radial extracorporeal shock wave intervention in hemiplegic shoulder pain, as well as to explore the relationships between sonographic structural changes and hemiplegic shoulder pain. this study will be a benefit in the physical therapy field and may guide rehabilitation programs of physical therapy towards better results through decreasing time needed to perform activity of daily living, decreasing dependency and making patient an active member in society.

Eligibility criteria:
inclusion criteria: * 1. patient's age ranges from 40 to 60 years. 2. spasticity of upper limb ranges from mild to moderate (grade 1+: 2) according to modified aschworth scale (mas). 3. patients with sufficient cognitive abilities that enables them to understand and follow instructions (mini-mental scale \>24). 4. patient who understand the study process and signed the informed consent form. 5. patient with stroke more than 3 months ago. 8. patient with shoulder pain and limited range of motion (rom) or loss of motion in the proximal arm on the hemiplegic side. exclusion criteria: * the following patients will be excluded from the study: 1. patients who cannot express their own pain intensity. 2. patients with a history of trauma or surgery to the shoulder on the affected side. 3. patients with history of oral nsaids 3 days before this study or take warfarin medication with an international normalized ratio above 4.0. 4. patients with a history of shoulder pain before the stroke. 6. patients who have received a previous shoulder intra-articular injection or other interventions on the affected shoulder within one month before reswt. 7. patients with cardiac pacemaker. 8. patients who have osteoporosis. 9. patients with psychological problems.

Keywords: sonography pain
a retrospective study with prospective follow-up of laparoscopic ventral hernia repair utilizing the bard sepramesh ip composite

Conditions: Hernia

Summary: this study will enroll subjects who underwent a laparoscopic ventral hernia repair utilizing sepramesh at least 12 months before starting in this study. the consented subjects' medical records will be reviewed for evidence of any risk factors of hernia recurrence, procedure time, complications and any documented recurrences. the subjects will be asked to undergo a physical exam to rule out any recurrences that were not documented in the medical records.


Eligibility criteria:
inclusion criteria: * have undergone a laparoscopic ventral repair utilizing sepramesh at least 12 months before starting in this study. * have signed an informed consent form (icf). exclusion criteria: * underwent implantation of sepramesh for any reason other than ventral hernia repair.
kinetics of response of cytomegalovirus with ganciclovir treatment using quantitative real-time pcr

Conditions: Cytomegalovirus Infections

Summary: the overall purpose of this research is to develop and use a blood test to better understand how quickly the viral drug ganciclovir works to clear infection with the cmv virus (cytomegalovirus) when it occurs. this test will potentially let doctors know early in the course of therapy when a virus is not responding well to the therapy and could therefore be resistant to the drug. the target population of this study will be primarily kidney and lung transplant patients with cmv detected in the blood, although other patients may also be included if they meet criteria. the study will be divided into two phases. phase i will evaluate a small number of exploratory patients initiating ganciclovir therapy and will require frequent blood sampling to obtain detailed information regarding the kinetic response of the virus to therapy. this information will be analyzed to help guide decisions regarding the number and frequency of blood samples needed in the larger phase ii portion of the study. strains will be characterized using phenotypic and genotypic methods to determine the presence or absence of mutations potentially responsible for the resistance.


Eligibility criteria:
inclusion criteria: * patients affiliated with barnes-jewish hospital with cmv blood infection requiring antiviral therapy * all patients will have a positive qualitative cmv pcr or viral culture before starting therapy * patients will receive treatment with ganciclovir at a dose and duration to be determined by the provider * it is anticipated that most subjects will be organ transplant recipients but this is not a requirement of the study exclusion criteria: * critically ill patients * patients with profound leukopenia or abnormal renal function that make a change in the antiviral drug dosage likely during the duration of the study * anemia (hgb \< 8 g/dl) that would contraindicate the extra blood draws required by this study * problems with vascular access that would interfere with obtaining blood samples required by this study * residence outside of the st. louis metropolitan area during the period of ganciclovir therapy * patients who are unable to provide informed consent because of diminished capacity related to illness, dementia, or other reasons

Keywords: cytomegalovirus viremia
patent foramen ovale closure in migraine

Conditions: Migraine; Patent Foramen Ovale

Summary: the goal of this observational study is to retrospectively observe the effect of pfo closure and medication on migraine. the main questions it aims to answer are: * whether pfo closure is more effective in the treatment of migraine than traditional medical treatment * what factors affect the effectiveness of migraine treatment ? participants will undergo contrast transthoracic echocardiography to diagnose pfo and evaluate right-to-left shunt. they will be treated with medication and pfo closure respectively according to guidelines. hit-6 and a questionnaire about migraine were obtained at the baseline and repeated at the 6-month and 12-month follow-up visits. researchers will compare closure group and drug group to see efficacy of two groups in treating migraine.

migraine patients with pfo who were admitted to our hospital from january 2018 to august 2021 were enrolled.they will be treated with medication and pfo closure respectively according to guidelines. headache impact test (hit-6) and a questionnaire about migraine were obtained at the baseline and repeated at the 6th and 12th month follow-up visits. 1. hit-6 was used to assess migraine severity. 2. questionnaire included questions regarding average duration of migraine, migraine frequency, relief of migraine after treatment, family history and medication use. 3. △hit-6 is the difference between baseline and follow-up in hit-6 and is used to assess migraine relief. the days of migraine attacks per month (mad) were calculated by the product of the frequency of headache attacks and average duration of each attack. therefore, the days of migraine remission per month (mrd)= mad at the 6th or 12th month follow-up- mad at baseline. in comparison with baseline, 50% decrease in the number of total attacks was considered responder. 4. four parameters were selected to evaluate the treatment effect: hit-6, △hit-6, mrd, and response rate.

Eligibility criteria:
inclusion criteria: closure group: * migraine patients with grade ii-iii rls of pfo confirmed by ctte. * hit-6≥50. * meeting the surgical indications of pfo closure according to chinese expert consensus on prophylactic closure of patent foramen ovale published in march 2017 * patients who have underwent pfo closure. drug group: * migraine patients with grade ii-iii rls of pfo confirmed by ctte. * hit-6 ≥ 50. * patients who have underwent drug treatment for 12 months. exclusion criteria: * congenital heart diseases, cardiomyopathy, heart failure, valvular heart disease, arrhythmia, severe hypertension or other heart diseases. * patients with serious complications after closure. * patients who have other known triggers of migraine. * patients with incomplete follow-up data.
impact of the use of feelwell™ compression garment on individuals with a bmi ≥35

Conditions: Obesity; Obesity, Abdominal; Mobility Limitation; Quality of Life; Back Pain; Pain, Chronic; Weight Change, Body; Inactivity; Exercise; Body Composition; Redundant Skin

Summary: to assess the effect of wearing a custom-fitted, fda-registered, class i device, compression garment (obesinov, s.a.r.l.) by an individual with a bmi ≥ 35 on his/her day-to-day quality of life over a period of one year. various measures of quality of life will be taken, including assessing an individual's level of pain, mood, self-stigma and comfort with the use of a compression garment. additionally, to assess the impact of the compression garment on activity, strength, posture and movement of an individual with a bmi ≥35 over the period of one year.

individuals suffering with obesity often experience daily pain and discomfort which limits movement, a critical factor in managing weight, cardio-metabolic health, mood, sleep, self-esteem and ultimately overall quality of life. many individuals who experience weight gain have an abdominal or central distribution of weight which affects body mechanics leading to back pain, poor posture, difficulty walking with altered gait, knee, foot, ankle and leg pain (it band, meralgia paresthetica) and other non-specific chronic pain. chronic pain impedes mobility often incorporating depression and low motivation in an endless cycle. furthermore, as individuals are losing weight, they often suffer from excess skin which also aggravates by chafing (arms, inner thighs), hanging down and interfering with gait. the investigators will examine the effect of wearing a custom-fitted, fda-registered, class i device, compression garment (obesinov, s.a.r.l.) by participants with a bmi ≥ 35 on day-to-day quality of life over a period of one year. various measures of quality of life will be taken, including assessing the participant's level of pain, mood, self-stigma and comfort with the use of a compression garment. additional assessments include impact of the compression garment on activity, strength, posture and movement as well as potential impact of the use of this garment on weight loss and change in laboratory measures of metabolic health.

Eligibility criteria:
inclusion criteria: * male or female, over 18 years old. * subjects with a bmi of ≥ 35. * subjects in any stage of weight loss or maintenance. exclusion criteria: * inability to put on or have help in putting on garment. * inability to participate in movement and exercise intervention. * panniculus grade \>3 at baseline or other body habitus that limits mobility. * duke activity status index (dasi) score \< 3.62 * medical condition limiting participation in trial or basic mobility. * current participation in a physical therapy program. * unwillingness to participate fully in trial. * participation in another trial at the same time. * patient health questionnaire (phq)-9≥15. * current or expected pregnancy * investigator's discretion

Keywords: compression garment physical therapy obesity movement abdominal binder
optimizing pulsatility during cardiopulmonary bypass

Conditions: Endothelial Dysfunction; Acute Kidney Injury

Summary: cardiopulmonary bypass during cardiac surgery provides blood flow to the body during surgery but has adverse effects on different organs. blood flow during cardiopulmonary bypass may be pulsatile or non-pulsatile, which may impact normal organ function after surgery. the study will collect data on the type of cardiopulmonary bypass used during surgery and organ function to determine if there is an association between the type of bypass and organ function.

cardiac surgery is a high-risk elective surgical procedure frequently requiring cpb in which a machine pumps blood while the surgeon operates on the heart. cpb contributes to surgical risk by causing endothelial dysfunction and acute kidney injury (aki). endothelial dysfunction and aki happen because heart lung machines typically generate non-pulsatile blood flow, which is abnormal and results in impaired tissue oxygen delivery. normal blood flow is pulsatile due intermittent contraction and relaxation of the heart during the cardiac cycle, which produces a mechanical signal that induces endothelial cells to produce nitric oxide. without nitric oxide, blood flow does not penetrate as deeply into organs such as the kidneys which leads to acute kidney injury. aki increases mortality 10-fold after cardiac surgery placing many people at risk since over 400,000 people have surgery with cpb each year in the united states. thus, pulsatile cpb may influence endothelial function and renal blood flow after cardiac surgery. this study will observe patients undergoing cardiac surgery with cpb and compare patients who receive pulsatile or non-pulsatile cpb.

Eligibility criteria:
inclusion criteria: * age 50 to 70 * able to provide informed consent * scheduled for elective cardiac surgery with cardiopulmonary bypass exclusion criteria: * patients undergoing emergency procedures * diagnosed with sepsis * experiencing delirium * experiencing hemodynamic instability (heart rate \> 100 and systolic blood pressure \< 90) * patients with a mechanical circulatory support device * requiring vasoactive medications before surgery * patients with a reduced left ventricular ejection fraction (less than 50%) * patients with a contraindication to transesophageal echocardiography

Keywords: endothelial function acute kidney injury cardiopulmonary bypass cardiac surgery
a multinational survey-based study to understand the real-world awareness and perceptions of systemic inflammation and role of hscrp as a biomarker in patients with atherosclerotic cardiovascular disease and chronic kidney disease among cardiologists

Conditions: Atherosclerotic Cardiovascular Disease (ASCVD); Chronic Kidney Disease (CKD)

Summary: the purpose of this survey is to collect information for scientific research and to better understand the role of systemic inflammation in identification, treatment and management of patients with ascvd and ckd. this study is a cross-sectional design conducted among cardiologists in united kingdom, italy, germany, brazil, saudi arabia, japan, australia, china, india and france, treating ascvd and ckd patients. study participants will be recruited to complete an approximately 20-minute self-administered online survey. recruitment will be conducted through email and phone. data is collected though online data collection using a programmed survey.


Eligibility criteria:
inclusion criteria: 1. informed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol). 2. male or female, age above or equal to 18 years at the time of signing informed consent. 3. is a cardiologist. 4. has been in practice greater than or equal to 3 years. 5. sees at least 15 ascvd and ckd patients per month. exclusion criteria: 1. previous participation in this study. participation is defined as having given informed consent in this study 2. mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation 3. does not meet inclusion criteria requirements
effect of acetazolamide on central sleep apnea related to opium consumption

Conditions: Central Sleep Apnea, Secondary

Summary: acetazolamide improves central sleep apnea related to opium consumption.

this is a double-blind, placebo-controlled, cross-over designed study to evaluate the effect of acetazolamide on central apneas in opium-user patients. we are going to invite 12 eligible patients to enter our study. this sample will be obtained from the referral patients to masih daneshvari hospital sleep lab. eligible patients will undergo a full night polysomnography (psg) to have a new measure of apnea indexes as baseline. epwoth sleepiness scale questionnaire (ess) will be filled by the patient the night of the study.also an arterial blood sample will be obtained at the morning of each study. if the patient have more than 5 central apneas in each hour he/she will be scheduled to randomly receive a box containing 6 capsules to use one hour before bedtime at coming nights. the prescriber physician who will also score the tests and the patients are unaware either these capsules are acetazolamide 250mg or placebo. at 6th night we will perform psg together with ess questionnaire and arterial blood gas (abg). after 2 weeks washout the patient receive another box containing 6 capsules with similar appearance to previous ones. if the patient receives acetazolamide in the first six nights, he/she will receive placebo in the second phase of the study and if the patient receives placebo in the first phase, he/she will receive acetazolamide in the second phase. after the second 6 days, the third psg will be performed plus ess measurement and morning abg sampling. coded polysomnograms will be scored blindly.

Eligibility criteria:
inclusion criteria: * opium or opioid use for at least two months in a daily manner * presence of five or more central sleep apnea per hour in a full-night recorded psg exclusion criteria: * congestive heart failure * living in high altitude * chronic obstructive pulmonary disease (copd) * carbon dioxide partial pressure (pco2) elevation due to other respiratory diseases * body mass index (bmi) \> 32 * obesity hypoventilation syndrome * severe renal or liver disorders * using benzodiazepine * using theophylline

Keywords: acetazolamide central sleep apnea opium abuse
effect of eyelid patching after ptosis surgery

Conditions: Ptosis, Eyelid

Summary: the goal of this randomized, controlled, observer-blinded study is to compare the effect of compression dressing after ptosis surgery. the main question it aims to answer are: effect of dressing on edema, hematoma, scar formation, ocular surface irritation and postoperative pain. patients are randomized after surgery for compression dressing or not. results are scored by a blinded observer. type of study: clinical trial


Eligibility criteria:
inclusion criteria: * ptosis exclusion criteria: * kongenital ptosis, pre-surgery, trauma

Keywords: ptosis, blepharoplasty, eyelid surgery